Compare Biogen Inc (BIIB) vs Dropbox Inc (DBX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Dropbox Inc — how do they compare? Biogen Inc trades at $203.97 (market cap $30.13B), while Dropbox Inc trades at $33.19 (market cap $7.41B). The key difference: Biogen Inc is far larger — about 4.1× Dropbox Inc's market cap. Which is the better fit depends on your goals.
| BIIB | DBX | |
|---|---|---|
Market Cap | $30.13B | $7.41B |
Sector | Health | Technology |
52-Week High | $216.63 | $35.00 |
52-Week Low | $128.93 | $22.06 |
Enterprise Value | $37.20B | $10.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
DBX trades at $34.59, down 0.63% today, with a bullish technical signal from moving averages and recent earnings beats. Revenue remains steady at $2.52B for 2025, with a net income margin of 20.16%. The company raised its 2026 outlook after Q2 results, supported by core file-sync-and-share growth and AI expansion. Cash flow from operations improved to $952M in 2025, though net cash flow was negative due to financing activities.
The outlook is mixed; strong profitability and bullish analyst coverage contrast with high debt levels and negative shareholder equity. Risks include competitive pressures and reliance on sustained user growth. With 37.5% of analysts rating it a buy, the stock offers growth potential but requires monitoring of balance sheet health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
